Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-(Aminosulfonyl)-N-[(3,4,5-trifluorophenyl)methyl]-benzamide is a synthetic small molecule compound with the molecular formula C14H11F3N2O3S and a molecular weight of approximately 344.31 g/mol[1][2][7]. It is classified as an experimental drug and has not been approved for any therapeutic use[2]. The compound acts as a potent inhibitor of human carbonic anhydrase II (CA2), binding with high affinity (Kd ≈ 3.9 nM)[2][10]. Structural studies have shown that it interacts specifically with the active site of CA2 through fluoroaromatic interactions[6], making it useful in biochemical research on enzyme inhibition. There are no known clinical indications or ongoing clinical trials for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-(Aminosulfonyl)-N-[(3,4,5-trifluorophenyl)methyl]-benzamide.